Shots:

• Ionis to receive $35M upfront- $55M as future milestones and royalties on net sales. Biogen to get worldwide development and commercialization rights and will be responsible for cost of further development and manufacturing
• The option to license is exercised- based on P-I study (N=70) of BIIB067 vs PBO- demonstrating lowering of SOD1 protein levels in CSF and proved to be safe and well-tolerated
• BIIB067 is an antisense oligonucleotide (ASO) RNase H-mediated inhibitor of SOD1 Mrna- targeted to treat ALS with SOD1 mutations

Ref: Biogen | Image:The Street